Intervention not reported
Local‐regional recurrence Radiology · patients with resectable thoracic esophageal cancer
The intervention showed no clear difference in local‐regional recurrence Radiology (moderate certainty).
1 finding from 1 review
Intervention not reported
Distant recurrence Radiology · patients with resectable thoracic esophageal cancer
The intervention showed no clear difference in distant recurrence Radiology (moderate certainty).
1 finding from 1 review
Intervention not reported
Any complication Clinical · patients with resectable thoracic esophageal cancer
The intervention showed no clear difference in any complication Clinical (moderate certainty).
1 finding from 1 review
Intervention not reported
Postoperative death Clinical · patients with resectable thoracic esophageal cancer
The intervention showed no clear difference in postoperative death Clinical (low certainty).
1 finding from 1 review
Intervention not reported
Anastomotic leaks Clinical/radiology · patients with resectable thoracic esophageal cancer
The intervention showed no clear difference in anastomotic leaks Clinical/radiology (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High
Intervention not reported
Progression‐free 5‐year survival2 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1170 participants
High
Intervention not reported
Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Progression‐free 10‐year survival4 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Adverse events · women with stage I/II epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review